Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Technique d'Aspiration Continue Double Avec Système Zoom pour l'Accident Vasculaire Cérébral (ADAPT 2 0)

3 novembre 2026 mis à jour par: Imperative Care, Inc.

Évaluation clinique de la technique d'aspiration double continue avec le système Zoom pour les accidents vasculaires cérébraux (ADAPT 2.0)

This study is designed to evaluate the effectiveness, safety and clinical performance of ADAPT 2.0, first-line aspiration neurothrombectomy with Zoom System with Continuous Dual Aspiration Technique (CDAT).

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Type d'étude

Observationnel

Inscription (Estimé)

750

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Alabama
      • Huntsville, Alabama, États-Unis, 35801
        • Recrutement
        • Huntsville Hospital
        • Contact:
          • Farrar Hickey
        • Chercheur principal:
          • R. Dana Tomalty, MD
    • California
      • Walnut Creek, California, États-Unis, 94598
        • Recrutement
        • John Muir Health
        • Chercheur principal:
          • Benjamin Yim, MD
        • Contact:
          • Melenie Aaron
    • Florida
      • Tampa, Florida, États-Unis, 33606
        • Recrutement
        • University of South Florida
        • Chercheur principal:
          • Maxim Mokin, MD
        • Contact:
          • Kilaun Robinson
    • Georgia
      • Marietta, Georgia, États-Unis, 30060
        • Recrutement
        • Wellstar Kennestone Hospital
        • Contact:
          • Autumn Lee
        • Chercheur principal:
          • Ahmad Khaldi, MD
    • Louisiana
      • Lafayette, Louisiana, États-Unis, 70503
        • Recrutement
        • Ochsner Clinic Foundation (Lafayette)
        • Chercheur principal:
          • Shail Thanki, MD
      • New Orleans, Louisiana, États-Unis, 70121
        • Recrutement
        • Ochsner Clinic Foundation
        • Chercheur principal:
          • James Milburn, MD
        • Contact:
          • Jessica Henry
    • Maryland
      • Baltimore, Maryland, États-Unis, 21201
        • Recrutement
        • University of Maryland
        • Chercheur principal:
          • Jacob Cherian, MD
        • Contact:
          • Katie Henry
    • Minnesota
      • Minneapolis, Minnesota, États-Unis, 55407
        • Recrutement
        • Allina Health
        • Contact:
          • Emeryth Beloy
        • Chercheur principal:
          • Collin Torok, MD
    • New York
      • Albany, New York, États-Unis, 12208
        • Recrutement
        • Albany Medical College
        • Chercheur principal:
          • Alexandra Paul, MD
        • Contact:
          • Chelsey Large
      • Buffalo, New York, États-Unis, 14203
        • Recrutement
        • University at Buffalo Neurosurgery
        • Chercheur principal:
          • Jason Davies, MD
        • Contact:
          • Ellen Carl
      • New York, New York, États-Unis, 10065
        • Recrutement
        • Weill Cornell Medicine
        • Contact:
          • Hanah Hwang
        • Chercheur principal:
          • Amol Mehta, MD
      • New York, New York, États-Unis, 10029
        • Recrutement
        • Icahn School of Medicine at Mount Sinai
        • Contact:
          • Kevin Buttet
        • Chercheur principal:
          • Michael T Caton, MD
      • Syracuse, New York, États-Unis, 13210
        • Recrutement
        • SUNY Upstate Medical Center
        • Contact:
          • Saptarshi Prachi
        • Chercheur principal:
          • Haydn Hoffman, MD
      • The Bronx, New York, États-Unis, 10467
        • Recrutement
        • Montefiore Medical Center
        • Contact:
          • Genesis Liriano
        • Chercheur principal:
          • Amanda Baker, MD
    • Ohio
      • Cincinnati, Ohio, États-Unis, 45220
        • Recrutement
        • TriHealth Good Samaritan Hospital
        • Chercheur principal:
          • Andrew Ringer, MD
        • Contact:
          • Mehnaaz Ali
    • Oklahoma
      • Oklahoma City, Oklahoma, États-Unis, 73104
        • Recrutement
        • University of Oklahoma, Health Science Center
        • Chercheur principal:
          • Hakeem Shakir, MD
        • Contact:
          • Sanaa Hameed
    • South Carolina
      • Greenville, South Carolina, États-Unis, 29605
        • Recrutement
        • Prisma Health - Upstate
        • Contact:
          • Shawn Manos
        • Chercheur principal:
          • Jan Vargas Machaj, MD
    • Tennessee
      • Knoxville, Tennessee, États-Unis, 37902
        • Recrutement
        • Fort Sanders Regional Medical Center
        • Contact:
          • Cameron Carter
        • Chercheur principal:
          • Robert Hixson, MD
      • Memphis, Tennessee, États-Unis, 38120
        • Recrutement
        • Semmes Murphey Foundation
        • Chercheur principal:
          • Lucas Elijovich, MD
        • Contact:
          • Wendell Barnett
    • Texas
      • Kingwood, Texas, États-Unis, 77339
        • Recrutement
        • HCA Houston Healthcare Kingwood
        • Chercheur principal:
          • Mohamad Ezzeldin, MD
        • Contact:
          • Swathi Potla
      • San Antonio, Texas, États-Unis, 78229
        • Recrutement
        • Methodist Healthcare System of San Antonio
        • Contact:
          • Samantha Franklin
        • Chercheur principal:
          • Lee Birnbaum, MD
      • San Antonio, Texas, États-Unis, 78229
        • Recrutement
        • University of Texas Science Health Center at San Antonio
        • Chercheur principal:
          • Justin Mascitelli, MD
        • Contact:
          • Athena Lazaris-Conner
    • Utah
      • Salt Lake City, Utah, États-Unis, 84112
        • Recrutement
        • University of Utah
        • Contact:
          • Andrew Grandemange
        • Chercheur principal:
          • Robert Rennert, MD
    • Virginia
      • Falls Church, Virginia, États-Unis, 22042
        • Recrutement
        • Inova Fairfax Medical Campus
        • Contact:
          • Lauren Monroe
        • Chercheur principal:
          • James McEachern, MD
    • Washington
      • Spokane, Washington, États-Unis, 99204
        • Recrutement
        • Providence Sacred Heart Medical Center and Children's Hospital
        • Contact:
          • Kyle Kramer
        • Chercheur principal:
          • Christopher Zylak, MD

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Adult subjects with acute ischemic stroke secondary to large vessel occlusion (LVO) meeting the study eligibility criteria and providing written informed consent.

La description

Inclusion Criteria:

  1. Subject is ≥ 18 years of age
  2. Subject or legally authorized representative has provided written informed consent prior to any study-specific procedures and no later than 72 hours after the index procedure
  3. Pre-stroke mRS 0-2
  4. Subject is undergoing or has undergone an aspiration thrombectomy using the Zoom System with Continuous Dual Aspiration Technique (CDAT) as the first line device within its intended use

Exclusion Criteria:

  1. Subjects with a life expectancy of less than 6 months
  2. Female subject who is known to be pregnant at time of admission
  3. Any intracranial hemorrhage in the qualifying head CT or MRI
  4. Presence of tandem internal carotid artery occlusion, multiple occlusion locations (e.g., cavernous ICA and M1, separate M2 occlusions, etc.), or occlusions in multiple territories (e.g., MCA and ACA, bilateral, etc.).
  5. In the opinion of the Investigator, the patient is not a suitable candidate for intervention with the Zoom System
  6. Subject is currently enrolled in or planned to be enrolled in any concurrent interventional study that may impact the safety or performance data collected in this study

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: PROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
ADAPT 2.0: Zoom System with Continuous Dual Aspiration Technique (CDAT)

The Zoom System is intended to be used as the first-line device and utilized within the FDA-cleared indications for use, consistent with the approved labeling and intended anatomical targets.

Aspiration neurothrombectomy using Zoom System with Continuous Dual Aspiration Technique (CDAT)

Autres noms:
  • ADAPT 2.0
  • Thrombectomie par aspiration pour accident vasculaire cérébral
  • Aspiration double continue
  • Thrombectomie par aspiration neurovasculaire

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Proportion of patients achieving modified Thrombolysis in Cerebral Infarction (mTICI) score of ≥2c at the end of procedure, as adjudicated by independent core-lab
Délai: End of procedure

mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches

End of procedure
Rate of Embolization to New Territory (ENT) on final angiography at the end of the procedure by investigator assessment
Délai: End of procedure

Embolization to New Territory (ENT), defined as the presence of new occlusions on final angiography that occur in vascular territories remote from those effected by index stroke, as assessed by the investigator

End of procedure

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Time to achieve mTICI≥2c, defined as groin puncture to investigator assessment for mTICI≥2c
Délai: Intraprocedural

The time from groin puncture to mTICI (modified treatment in cerebral infarction) score ≥ 2c using study device and technique.

mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches

Intraprocedural
Proportion of cases with clot ingestion, as evidenced by clot captured within the Zoom POD
Délai: Intraprocedural

Proportion of cases with clot ingestion, as evidenced by clot captured within at least one of the Zoom PODs

Intraprocedural
Proportion of cases with clot captured within the Zoom POD connected to the outer aspiration catheter
Délai: Intraprocedural

Proportion of cases with clot ingestion, as evidenced by clot captured within the outer Zoom PODs

Intraprocedural
Rate of rescue therapy
Délai: Intraprocedural

Proportion of cases with rescue therapy, defined as unplanned use of another manufacturer's thrombectomy device, angioplasty, or stenting within the target vessel territory to achieve mTICI≥2c.

Intraprocedural
Rate of functional independence (mRS 0-2) at 90 days
Délai: 90 days post-procedure

Proportion of patients achieving mRS (modified Rankin Scale) ≤2 at 90 days

mRS range: 0 to 6; The mRS scale ranges from 0 (no symptoms) to 5 (severe disability), with an additional category of 6 for death; higher score means worse outcome

90 days post-procedure
Proportion of patients achieving First Pass Effect (FPE) mTICI ≥2c as adjudicated by independent core-lab
Délai: Intraprocedural

Proportion of cases achieving First Pass Effect (FPE), defined as mTICI ≥2c after the first pass with the study device and technique as adjudicated by independent core-lab

mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches

Intraprocedural
Rate of symptomatic intracranial hemorrhage (sICH), as confirmed by imaging and independently adjudicated by medical monitor, at the 24-hour post-procedure
Délai: 24-hour post-procedure

Independently adjudicated rate of symptomatic intracranial hemorrhage (sICH) defined as any apparently extravascular blood in the brain or within the cranium confirmed by imaging that is associated with clinical deterioration as defined by an increase of four or more points in the NIHSS at 24 hours compared to the baseline assessment, or that led to death, and was judged to be the predominant cause of a neurologic deterioration or death, per ECASS III criteria

24-hour post-procedure
90-day all-cause mortality
Délai: 90 days post-procedure

Rate of all-cause mortality through 90 days post-procedure

90 days post-procedure
Rate of device-related Serious Adverse Events, independently adjudicated medical monitor
Délai: Intraprocedural

Independently adjudicated rate of Serious Adverse Events related to study device

Intraprocedural

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: David Fiorella, MD, Stony Brook University Hospital
  • Chercheur principal: Shahram Majidi, MD, Icahn School of Medicine at Mount Sinai
  • Chercheur principal: Justin Masciteli, MD, The University of Texas Health Science Center at San Antonio
  • Chercheur principal: Maxim Mokin, MD, University of South Florida

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

24 mars 2026

Achèvement primaire (Estimé)

31 mars 2030

Achèvement de l'étude (Estimé)

1 juin 2030

Dates d'inscription aux études

Première soumission

17 mars 2026

Première soumission répondant aux critères de contrôle qualité

24 mars 2026

Première publication (Réel)

25 mars 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

6 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

3 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Oui

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner